California Public Employees Retirement System Sells 111,602 Shares of Regeneron Pharmaceuticals, Inc. $REGN

California Public Employees Retirement System lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 35.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 203,114 shares of the biopharmaceutical company’s stock after selling 111,602 shares during the period. California Public Employees Retirement System owned about 0.19% of Regeneron Pharmaceuticals worth $114,205,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Osaic Holdings Inc. raised its position in Regeneron Pharmaceuticals by 55.2% during the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after purchasing an additional 6,073 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its position in shares of Regeneron Pharmaceuticals by 153.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after buying an additional 73,176 shares during the last quarter. PGGM Investments grew its position in shares of Regeneron Pharmaceuticals by 9.7% in the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock worth $52,057,000 after buying an additional 8,187 shares during the last quarter. Sound Shore Management Inc CT purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $64,677,000. Finally, Rakuten Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $33,121,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 5,274 shares of company stock valued at $4,142,738. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $756.91 on Tuesday. The business’s fifty day moving average is $769.61 and its 200 day moving average is $696.93. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock has a market cap of $80.02 billion, a price-to-earnings ratio of 18.21, a PEG ratio of 2.00 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm posted $12.07 earnings per share. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were given a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

Analyst Ratings Changes

A number of analysts recently commented on the company. JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $802.27.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.